Development of antiviral therapy for severe acute respiratory syndrome

A new disease, the severe acute respiratory distress syndrome (SARS), caused by the SARS coronavirus (SARS-CoV), emerged at the beginning of 2003 and rapidly spread throughout the world. Although the disease had disappeared in June 2003 its re-emergence cannot be excluded. The development of vaccine...

Full description

Saved in:
Bibliographic Details
Published in:Antiviral research 2005-06, Vol.66 (2), p.81-97
Main Authors: Cinatl, Jindrich, Michaelis, Martin, Hoever, Gerold, Preiser, Wolfgang, Doerr, Hans Wilhelm
Format: Article
Language:English
Subjects:
Animals
Anti-viral therapy
Antibiotics. Antiinfectious agents. Antiparasitic agents
Antiviral agents
Antiviral Agents - therapeutic use
Biological and medical sciences
Coronavirus Infections - drug therapy
Coronavirus Infections - epidemiology
Coronavirus Infections - prevention & control
Coronavirus Infections - transmission
Disease Outbreaks
Drug Design
Humans
Medical sciences
Pharmacology. Drug treatments
Review
Ribavirin
SARS coronavirus
SARS Virus - drug effects
SARS Virus - immunology
SARS-CoV
Severe Acute Respiratory Syndrome - drug therapy
Severe Acute Respiratory Syndrome - epidemiology
Severe Acute Respiratory Syndrome - prevention & control
Severe Acute Respiratory Syndrome - transmission
Viral Vaccines - immunology
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A new disease, the severe acute respiratory distress syndrome (SARS), caused by the SARS coronavirus (SARS-CoV), emerged at the beginning of 2003 and rapidly spread throughout the world. Although the disease had disappeared in June 2003 its re-emergence cannot be excluded. The development of vaccines against SARS-CoV may take years. Therefore, the availability of effective antiviral drugs against SARS-CoV may be crucial for the control of future SARS outbreaks. In this review, experimental and clinical data about potential anti-SARS drugs is summarised and discussed. Animal model studies will be needed to help to determine which interventions warrant controlled clinical testing.
ISSN:0166-3542
1872-9096
DOI:10.1016/j.antiviral.2005.03.002